Home

Novel luciferase reporter provides optimal performance in high-throughput screens of G-protein-coupled agonist binding. Background: G-protein-coupled receptors (GPCRs) constitute the largest class of cell surface receptors. GPCR genes account for 5% of the human genome. GPCRs also represent the largest and among the most efficacious classes of therapeutic targets for diseases including cardiovascular disease, cancer, and asthma.  Technology Overview:  The novel cyclic adenosine monophosphate (cAMP)-responsive luciferase  reporter exhibits optimal performance in high-throughput screens of agonist binding at GPCRs. This reporter exhibits substantially reduced basal activity, a feature that is likely to be of particular importance when performing high-throughput screens in which false-positive hits are to be avoided. Compared to other reporters, the present construct affords a much wider dynamic range of activation (>340 fold-stimulation) upon exposure to GPCR agonists with cAMP signaling properties. https://suny.technologypublisher.com/files/sites/2009-110.jpghttps://www.pexels.com/photo/scientist-in-laboratory-3735769/ Advantages:  

• Significantly reduced basal luciferase activity inherent to similar reporters.
• Wide dynamic range of activation upon exposure to agonist.

   Applications:  

• Research tool
• Drug candidate high-throughput screening

 

­A killed ZIKA vaccine that prevents infection and is safe for pregnant women. Background:
Zika virus (ZIKV) is a Flavivirus transmitted by mosquitoes. First discovered in 1947, it remained a minor infectious entity until 2007, when the first large outbreak was reported in Micronesia. Subsequent severe outbreaks in French Polynesia (2013-14) and in Brazil (2015) put ZIKV on the map. Those outbreaks showed that Zika Virus is not only transmitted by mosquitos, but also by sexual contact and in utero, from Mom to fetus. While most people infected with ZIKV have few to no symptoms; the outbreak in Brazil was associated with increased microencephaly, with other severe congenital malformations, and with neurological complications.By 2016, 39 countries and territories in the Americas had confirmed local, vector-borne transmission of ZIKV as well as superinfection from one person to another. That, coupled with the severity of symptoms, triggered a campaign to create a robust ZIKV vaccine.Technology Overview:  
In a collaborative effort, scientists in the Army and at SUNY have created and tested a killed ZIKA vaccine. It has undergone Phase 1 and 2 testing in pregnant mouse and pregnant marmoset models. It has also been tested in humans.
Further Details:

1. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2020 Sep;20(9):1061-1070. doi: 10.1016/S1473-3099(20)30085-2. Epub 2020 May 6. PMID: 32618279; PMCID: PMC7472641. (https://pubmed.ncbi.nlm.nih.gov/32618279/) 
2. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. Erratum in: Lancet. 2020 Jun 20;395(10241):1906. PMID: 29217375; PMCID:PMC5884730. (https://pubmed.ncbi.nlm.nih.gov/29217375/) 
3. Sci Transl Med. 2017 Dec 13;9(420):eaao4163. doi: 10.1126/scitranslmed.aao4163. Erratum in: Sci Transl Med. 2018 Jul 18;10(450):PMID: 29237759; PMCID: PMC5747972. (https://pubmed.ncbi.nlm.nih.gov/29237759/)

https://suny.technologypublisher.com/files/sites/adobestock_1194681161.jpegAdvantages:  
 
•    Broad application  Applications:  

•    Prevention of ZIKV infection with a vaccine that is safe even for pregnant women.
 
Intellectual Property Summary: Zika virus vaccine and Methods of Production is protected by patent 11,033,615 which issued on June 15, 2021 https://patents.google.com/patent/US11033615B2/
Stage of Development:

TRL 4 – Technology validated in lab
Licensing Status:
This technology is available for licensing.
 

A novel protein purification tag achieves high yields of pure, soluble, full-length recombinant proteins  Background:Current protein purification methods rely on solubility-enhancing tags that permit purification with affinity chromatography and subsequent cleavage with specific proteases to extract the target proteins. Researchers have now developed a technique to recover target proteins from inclusion bodies using strategically developed fusion partners.Technology Overview:  This technology employs an engineered ribose binding protein (RBP), originally derived from a thermophilic anaerobic bacterium, to achieve high yields of pure, soluble, full-length recombinant proteins expressed in prokaryotic or eukaryotic cells. RBP is circularly permuted and split at a site that the researchers discovered to yield a native and unusually stable RBP structure, and the protein inserted at this site is protected against degradation by endogenous cellular exoproteases, stabilizing and increasing overexpression of target proteins. This technology has been used successfully to express, solubilize and purify human amyloid proteins under native conditions.  https://suny.technologypublisher.com/files/sites/2021-110.jpgAdvantages:  

• Selectively purifies full-length, non-degraded target proteins.
• Simple purification using Ni-NTA columns.
• Design protects target protein from degradation by cellular proteases.
• Peptides can be purified out of inclusion bodies.
• Can be easily integrated into other vectors.

 
Applications:  

• Recombinant or native protein purification.
• Can be used in prokaryotic and eukaryotic systems.
• Can solubilize and purify amyloid proteins.

 
Licensing Potential: This technology is vailable for licensing.

A surgical "sewing machine" for rapid graft quilting and suturing in challenging spaces. Background: Grafts are commonly employed in urologic reconstructive surgery, but anchoring them in less accessible areas -- as in luminal stenosis surgery -- can be difficult. A novel surgical "sewing machine" capable of quilting and suturing in tight spaces was developed to help solve this problem. Technology Overview: The repair of luminal stenosis involves an incision through the stenosed segments and followed by the application of a buccal mucosa graft to serve as protection. A surgical sewing machine was assembled by threading absorbable 4-0 barbed suture through a 20-gauge hollow needle. The result is rapid, one hand suturing for graft quilting, with a running stitch, akin to the way a sewing machine makes a continuous stitch across the hem of a skirt. This suturing device, developed by Upstate Medical University researchers, has been used in posterior urethroplasties, a transvesical bladder neck reconstruction, augmented perineal urethrostomy, and a vaginoplasty revision. In each case, the graft survived and there was no recurrence of disease. Advantages: - Higher rate of graft success with no recurrence of disease
- One handed suturing avoids alternating movements to reposition the needle, and is more efficient
- Can be used in a variety of complex reconstructive surgeries, including those involving radiated tissue, where graft fixation and suturing is challenging
- Future applications in endoscopic and laparoscopic surgery are possible. Intellectual Property Summary: Patent filed, 16/604,858, on Suturing Device And Methods Of Use Thereof   Licensing Potential: Licensing, Development partner, Commercial partner Licensing Status: This technology is available for licensing.  Licensing. ID: 110-2026 https://suny.technologypublisher.com/files/sites/110-2026skin_grafting.jpg